Repository hosted by TU Delft Library

Home · Contact · About · Disclaimer ·
 

Search results also available in MS Excel format.

Showing 1 to 4 of 4 found. | Sort by date

1 Interleukin 10: A new risk marker for the development of restenosis after percutaneous coronary intervention
article 2007    
Author: Monraats, P.S. · Kurreeman, F.A.S. · Pons, D. · Sewgobind, V.D.K.D. · Vries, F.R. de · Zwinderman, A.H. · Maat, M.P.M. de · Doevendans, P.A. · Winter, R.J. de · Tio, R.A. · Waltenberger, J. · Huizinga, T.W.J. · Eefting, D. · Quax, P.H.A. · Frants, R.R. · Laarse, A. van der · Wall, E.E. van der · Jukema, J.W.
Keywords: Health · Biomedical Research · alanine · clopidogrel · cysteine · glycine · interleukin 10 · ticlopidine · adult · aged · article · cardiovascular risk · confidence interval · controlled study · coronary artery bypass graft · disease marker · DNA flanking region · DNA microarray · drug eluting stent · female · gene linkage disequilibrium · gene locus · genetic association · genetic polymorphism · genetic predisposition · genetic risk · genetic variability · genotype · heart infarction · human · hypothesis · in-stent restenosis · major clinical study · male · pathogenesis · percutaneous coronary intervention · priority journal · risk factor · 3' Untranslated Regions · Aged · Angioplasty, Transluminal, Percutaneous Coronary · Coronary Restenosis · Female · Genetic Predisposition to Disease · Genotype · Humans · Inflammation · Interleukin-10 · Male · Middle Aged · Polymorphism, Genetic · Promoter Regions (Genetics) · Prospective Studies · Risk Factors · Treatment Outcome
[Abstract]

2 Drug-eluting stents studies in mice: Do we need atherosclerosis to study restenosis?
article 2006    
Author: Pires, N.M.M. · Jukema, J.W. · Daemen, M.J.A.P. · Quax, P.H.A.
Keywords: Health · Biomedical Research · (Histo)Pathology · Animal models · Atherosclerosis · Drug-eluting stents · Restenosis · 7 hexanoyltaxol · Dactinomycin · Dexamethasone · Everolimus · Paclitaxel · Paclitaxel derivative · Qp 2 · Rapamycin · Tacrolimus · Thalidomide · Unclassified drug · Artery intima proliferation · Atherosclerosis · Blood pressure variability · Clinical trial · Coronary stent · Cost effectiveness analysis · Disease exacerbation · Disease model · Drug efficacy · Drug eluting stent · Drug release · Drug safety · Evaluation · Healing impairment · Hypersensitivity reaction · In-stent restenosis · Mouse strain · Nonhuman · Pain · Rash · Respiratory tract disease · Restenosis · Side effect · Thrombosis · Animals · Atherosclerosis · Coronary Restenosis · Disease Models, Animal · Drug Delivery Systems · Drug Evaluation, Preclinical · Humans · Mice · Paclitaxel · Sirolimus · Stents
[Abstract]

3 Local perivascular delivery of anti-restenotic agents from a drug-eluting poly(ε-caprolactone) stent cuff
article 2005    
Author: Pires, N.M.M. · Hoeven, B.L. van der · Vries, M.R. de · Havekes, L.M. · Vlijmen, B.J. van · Hennink, W.E. · Quax, P.H.A. · Jukema, J.W.
Keywords: Biology · Biomedical Research · Animal model · Controlled drug release · Drug-eluting stents · Local delivery · Poly(ε-caprolactone) · Restenosis · Cardiology · Cell culture · Mathematical models · Muscle · Anti-restenotic agents · Contralateral femoral arteries · Drug-eluting stents (DES) · Interventional cardiology · Controlled drug delivery · Actin · Macrogol 300 · Macrogol derivative · Paclitaxel · Polycaprolactone · Polymer · Rapamycin · Unclassified drug · Animal experiment · Animal tissue · Artery intima proliferation · controlled study · Dose response · Drug delivery system · Drug formulation · Femoral artery · In vivo study · In-stent restenosis · Mouse · Nonhuman · Reproducibility · Smooth muscle fiber · Sustained drug release · Animals · Blood Vessel Prosthesis · Coated Materials, Biocompatible · Diffusion · Drug Carriers · Drug Implants · Femoral Artery · Graft Occlusion, Vascular · Immunosuppressive Agents · Male · Materials Testing · Mice · Mice, Inbred C57BL · Paclitaxel · Polyesters · Sirolimus · Stents · Animalia
[Abstract]

4 Activation of nuclear receptor Nur77 by 6-mercaptopurine protects against neointima formation
article 2007    
Author: Pires, N.M.M. · Pols, T.W.H. · Vries, M.R. de · Tiel, C.M.van · Bonta, P.I. · Vos, M. · Arkenbout, E.K. · Pannekoek, H. · Jukema, J.W. · Quax, P.H.A. · Vries, C.J.M. de
Keywords: Biology · Biomedical Research · Muscle, smooth · Receptors, cytoplasmic and nuclear · Restenosis · Stents · Transcription factors · cyclin dependent kinase inhibitor 1B · cycline · mercaptopurine · messenger RNA · nuclear receptor Nur77 · polycaprolactone · small interfering RNA · staurosporine · thymidine · tritium · animal experiment · animal model · animal tissue · antiangiogenic activity · antigen expression · apoptosis · artery intima proliferation · article · blood vessel injury · blood vessel wall · cell culture · cell cycle arrest · cell proliferation · controlled study · DNA synthesis · drug delivery system · drug dose comparison · drug effect · elution · experimental model · femoral artery · gene overexpression · human · human cell · hypothesis · in-stent restenosis · inflammation · intima · local therapy · male · mouse · nonhuman · observation · priority journal · protein expression · receptor down regulation · receptor upregulation · smooth muscle fiber · sustained drug release · transgenic mouse · vascular smooth muscle · wild type · 6-Mercaptopurine · Animals · Antimetabolites, Antineoplastic · Apoptosis · Cell Division · Cells, Cultured · Coronary Restenosis · Disease Models, Animal · DNA-Binding Proteins · Drug Implants · Femoral Artery · Humans · Male · Mice · Mice, Inbred Strains · Mice, Transgenic · Muscle, Smooth, Vascular · Receptors, Cytoplasmic and Nuclear · Receptors, Steroid · RNA, Messenger · RNA, Small Interfering · Transcription Factors · Tunica Intima · Umbilical Arteries
[PDF] [Abstract]

Search results also available in MS Excel format.

Showing 1 to 4 of 4 found. | Sort by date